// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Endobronchial valve lung volume reduction and small airways function

Justin Leo Garner - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Long-term effect of alpha-1-antitrypsin augmentation therapy on the decline of FEV1 in deficient patients

Iris G.M. Schouten - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Alpha-1 antitrypsin (A1AT) deficiency

Alpha 1-Antitrypsin

Association between COPD exacerbations and acute cardiovascular events: a systematic literature review

Hana Müllerová - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Superior laryngeal nerve block in chronic refractory cough

Caroline Wright - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Lidocaine

Tezepelumab efficacy in patients with severe, uncontrolled asthma and comorbid nasal polyps in NAVIGATOR

Andrew Menzies-Gow - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Asthma

Tezepelumab

Association between Th2 biomarker levels and efficacy of house dust mite sublingual allergy immunotherapy in adults with allergic asthma

Ilka Hoof - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Clinically Meaningful Improvement in Total Rhinoconjunctivitis Score with Olopatadine/mometasone Combination Nasal Spray in Patients with Seasonal Allergic Rhinitis: A Pooled Analysis

Eli O Meltzer - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Allergic rhinitis

Olopatadine hydrochloride

Population pharmacokinetic and exposure-response analyses to support fixed dosing of tezepelumab in patients with severe asthma

Yanan Zheng - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Tezepelumab

Transitioning from hospital-based biologic care to home care in a severe asthma patient population; a patients’ perspective

Ryan Robinson - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Benefits of triple therapy in moderate, severe, and very severe COPD: subgroup analysis of the ETHOS trial

Klaus F. Rabe - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

Seebri Breezhaler

Risk factors for all-cause mortality in patients with COPD: results from the ETHOS trial

Gary T. Ferguson - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

The association between health-related quality of life and COPD exacerbations measured by EQ-5D-5L in the ETHOS trial

Dan Jackson - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Predicting SGRQ score based on CAT score: post-hoc analysis of the IMPACT trial

Paul Jones - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Improvements in lung function with umeclidinium/vilanterol analysed by reversibility at screening: a post hoc analysis of the EMAX trial

Leif Bjermer - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Umeclidinium

Effect of tezepelumab on exacerbation-related oral corticosteroid use in NAVIGATOR

Arnaud Bourdin - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Tezepelumab

CAPTAIN: Effects of lung function at screening (FEV1 % predicted) as a continuous variable on treatment outcomes

Alberto Papi - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Umeclidinium

Efficacy of tezepelumab in adolescents with severe, uncontrolled asthma

Elliot Israel - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Tezepelumab

The burden of intermittent oral corticosteroid use in asthma

Heath Heatley - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Are patients with COPD more adherent to single-inhaler compared with multiple-inhaler triple therapy in a real-world UK primary care treated population?

Kieran Rothnie - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Relationship between prior triple therapy use and benefits of budesonide/glycopyrronium/formoterol on exacerbation risk: analysis from ETHOS

Dave Singh - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

Seebri Breezhaler

Copyright © 2026. QuantiNova All rights reserved